版本:
中国

BRIEF-European Commission approves Amgevita for treatment of certain inflammatory diseases

March 23 Amgen Inc

* European Commission approves Amgevita™ (biosimilar adalimumab) for the treatment of certain inflammatory diseases

* Amgen Inc- approval from EC grants a centralized marketing authorization with unified labeling in 28 countries that are members of EU Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐